This is a prospective cohort study. The investigators enroll subjects with pancreatic ductal adenocarcinoma (PDAC), individuals at high risk for PDAC, patients with other pancreatic diseases, patients with CA19-9 elevation and controls without pancreatic disease. This study aims to establish a diagnostic prediction model by using elastase 1, common clinical serological examinations, and imaging examinations including endoscopic ultrasonography (EUS), and to explore the diagnostic ability of the model in the high-risk population of PDAC. Besides, the investigators search for new biomarkers by multi-omics studies of serum and pancreatic tissues to further improve the diagnostic performance of this model. In conclusion, this study seeks a robust diagnostic prediction model to diagnose PDAC, especially early resectable PDAC.
Patients with pancreatic cancer with recognized diagnostic criteria or conclusions.
Patients who are the high-risk group of pancreatic cancer.
Patients with solid pseudo papilloma and neuroendocrine tumors of pancreas with recognized diagnostic criteria or conclusions.
Patients with other diseases with abnormally elevated CA19-9.
Patients who are younger than 18 years of age.
Patients with suspected pancreatic malignant lesions but has no confirmed imaging or pathological diagnosis.
Patients who have not signed informed consent.
6
Treatment groupsSee each treatment group below.
Qilu Hospital of Shandong University
Lead sponsor
First Affiliated Hospital, Sun Yat-Sen University
Collaborator
First Affiliated Hospital of Guangxi Medical University
Collaborator
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborator
LanZhou University
Collaborator